PBCay One RSC Ltd Buys Shares of 279,100 Danaher Corporation $DHR

PBCay One RSC Ltd purchased a new position in Danaher Corporation (NYSE:DHR) during the 1st quarter, HoldingsChannel.com reports. The firm purchased 279,100 shares of the conglomerate’s stock, valued at approximately $52,917,000. Danaher makes up 3.9% of PBCay One RSC Ltd’s investment portfolio, making the stock its 11th largest position.

Other large investors also recently bought and sold shares of the company. Elevated Capital Advisors LLC purchased a new stake in Danaher in the fourth quarter worth $26,000. Hilton Head Capital Partners LLC bought a new stake in shares of Danaher during the fourth quarter worth $27,000. Clal Insurance Enterprises Holdings Ltd boosted its stake in shares of Danaher by 71.6% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 53 shares during the period. JPL Wealth Management LLC bought a new position in shares of Danaher in the third quarter worth about $25,000. Finally, Main Street Group LTD purchased a new position in Danaher in the 1st quarter worth about $25,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Several commentary pieces say the post-earnings drop may have created a buying opportunity, with Barron’s arguing investors should not abandon Danaher (DHR) after the sharp reaction and suggesting the stock could rebound. Article: Don’t Quit on Danaher Stock After Horrific Earnings Reaction
• Positive Sentiment: One technical-market update said the selloff may be showing signs of capitulation, and noted some bullish trading activity in the shares, which could indicate downside pressure is easing. Article: Stock Of The Day: Is The Danaher Selloff Over?
• Positive Sentiment: Wall Street analysts still see meaningful upside from current levels, with one note highlighting a consensus price target implying about 32% potential gain and improving earnings estimate revisions. Article: Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect?
• Neutral Sentiment: Danaher’s Q2 2026 earnings call transcript was published, giving investors a fresh look at management’s commentary and the company’s outlook, but the transcript itself does not change fundamentals. Article: Danaher (DHR) Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Unusual options activity showed elevated put buying in Danaher (DHR), suggesting some traders are hedging for further downside or volatility after the earnings-driven move.
• Negative Sentiment: Recent coverage says the stock’s sharp decline was driven by Q2 results where a beat on earnings was overshadowed by bioprocessing weakness and analyst price-target cuts, which remain the main bearish overhang on the shares. Article: Stock Of The Day: Is The Danaher Selloff Over?

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on DHR shares. Evercore reiterated an “outperform” rating and set a $230.00 price objective on shares of Danaher in a report on Monday, July 6th. Rothschild & Co Redburn set a $205.00 target price on shares of Danaher in a research report on Friday, April 17th. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. The Goldman Sachs Group dropped their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Finally, Jefferies Financial Group restated a “buy” rating and set a $245.00 price objective on shares of Danaher in a report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average price target of $228.91.

Danaher Price Performance

NYSE DHR opened at $192.52 on Friday. The company has a market cap of $135.34 billion, a PE ratio of 34.20, a P/E/G ratio of 2.19 and a beta of 0.79. The firm’s 50 day moving average price is $185.05 and its 200-day moving average price is $197.07. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.52 and a current ratio of 1.65. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.Danaher’s revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.77 earnings per share. Sell-side analysts forecast that Danaher Corporation will post 8.51 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be given a $0.40 dividend. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.8%. Danaher’s payout ratio is presently 30.95%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.